[ Drugmaker AstraZeneca will cap out-of-pocket costs at $35 for all its inhaler products, the company announced Monday. The cap is effective June 1, and will apply to the company’s entire range of inhaler products used to treat asthma and chronic obstructive pulmonary disease (COPD), including inhalers like Symbicort, Breztri Aerosphere and Airsupra. The cap will … Read more
[ Drugmaker Boehringer Ingelheim plans to cap the out-of-pocket costs for all its inhalers at $35 per month after coming under fire from Democratic lawmakers over pricing. The company announced Thursday that the program will start June 1. It’s aimed at patients with employer-sponsored insurance, and those who are underinsured and uninsured, meaning they likely … Read more
[ Unexpected health costs and surprise medical bills are among the leading concerns of voters heading into the 2024 election, which contribute to their negative views about the economy, according to a new poll released Wednesday from health policy research group KFF. At least eight in ten voters said it was “very important” for the … Read more
[ A Texas federal judge on Monday dismissed a lawsuit challenging the Biden administration’s Medicare drug price negotiations filed by the pharmaceutical industry lobbying group PhRMA. The decision marks a small victory for the Biden administration, as it’s the first time a court has outright dismissed a challenge to Medicare’s new price negotiation powers. There … Read more
[ A new report released Tuesday by Sen. Bernie Sanders (I-Vt.) takes aim at the prices and executive compensation of three major drug manufacturers, previewing his lines of attack for when the companies’ CEOs appear at a hearing later this week. In the report prepared by Democratic staff on the Senate Health, Education, Labor and … Read more
[ Drugmaker Biogen said Wednesday it will give up its ownership of Aduhelm, the Alzheimer’s treatment drug that sparked intense criticism of the company and the Food and Drug Administration (FDA) after it was approved in 2021. The company will also terminate an ongoing post-approval clinical trial that the FDA ordered to confirm the … Read more
[ Sen. Tammy Baldwin (D-Wis.) is demanding the four largest manufacturers of inhalers to stop improperly listing patents in a Food and Drug Administration (FDA) database, a practice that can delay lower-cost generics from coming to market. In letters sent Monday to AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline (GSK) and Teva, Baldwin called on the companies to … Read more
[ Sen. Bernie Sanders (I-Vt.) and a group of Senate Democrats on Monday announced an investigation into the high costs of asthma inhalers. Sanders, chairman of the Senate Health, Education, Labor and Pensions (HELP) Committee, sent letters to the CEOs of the four biggest manufacturers of inhalers sold in the United States — AstraZeneca, Boehringer … Read more
